Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2025-0154
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
IBM TXSeries for Multiplatforms information disclosure
Source: NVD (National Vulnerability Database)
Vulnerability Description
IBM TXSeries for Multiplatforms 9.1 and 11.1 could disclose sensitive information to a remote attacker due to improper neutralization of HTTP headers.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N
Source: NVD (National Vulnerability Database)
Vulnerability Type
对HTTP头部进行脚本语法转义处理不恰当
Source: NVD (National Vulnerability Database)
Vulnerability Title
IBM TXSeries for Multiplatforms 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
IBM TXSeries for Multiplatforms是美国国际商业机器(IBM)公司的一种事务处理监控和管理的软件产品,它旨在支持多平台上的分布式事务处理。 IBM TXSeries for Multiplatforms 9.1版本和11.1版本存在安全漏洞,该漏洞源于HTTP标头中和不当,可能导致敏感信息泄露。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
IBMTXSeries for Multiplatforms 9.1 cpe:2.3:a:ibm:txseries_for_multiplatforms:9.1:*:*:*:*:*:*:*
II. Public POCs for CVE-2025-0154
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2025-0154
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2025-0154

No comments yet


Leave a comment